⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL154573 | 0.97 | NOS1 (0.35) | — | |
| SCHEMBL21305354 | 0.91 | SIGMAR1 (0.40) | — | |
| SCHEMBL31421098 | 0.84 | — | — | |
| SCHEMBL5672121 | 0.84 | — | — | |
| SCHEMBL1052281 | 0.84 | SIGMAR1 (0.48) | — | |
| SCHEMBL31420923 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL12817739 | 0.82 | — | — | |
| SCHEMBL25365 | 0.78 | — | — | |
| SCHEMBL203650 | 0.78 | SIGMAR1 (0.43) | — | |
| SCHEMBL11750040 | 0.78 | SIGMAR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | claimed |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-09 | — | — | US | claimed |
| EP-1805166-B1 | QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | claimed |
| US-7534891-B2 | Quinoline derivatives as H3R inverse agonists | HOFFMAN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | claimed |
| JP-2008517003-A | — | — | 2008-05-22 | — | — | JP | claimed |
| EP-1805166-A1 | QUINOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-11 | — | — | EP | claimed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | claimed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2006045416-A1 | QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | claimed |
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | claimed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | claimed |
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12617797-B2 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2026-05-05 | — | — | US | disclosed |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| US-4968697-A | ADENOSINE-2 RECEPTOR AGONISTS | CIBA-GEIGY CORPORATION (US) | 1990-11-06 | — | — | US | disclosed |
| US-4954504-A | Hypotensive agents, psychotic disorders | CIBA-GEIGY CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0354180-A2 | Certain imidazo[4,5-b]pyridine derivatives | CIBA-GEIGY AG (CH) | 1990-02-07 | — | — | EP | disclosed |
| EP-0323807-A2 | Certain 2-substituted adenosine derivatives | CIBA-GEIGY AG (CH) | 1989-07-12 | — | — | EP | disclosed |
| US-4119644-A | SYNTHETIC FIBERS | BASF AKTIENGESELLSCHAFT (DE) | 1978-10-10 | — | — | US | disclosed |